Close menu


Creation : 21/12/2021

Employees : 4

Adress : 11 Avenue Paul Verlaine – 38100 Grenoble

Activity : Biotech/Medtech



Who ?


With a patient-centred approach, our mission is to offer patients comprehensive management of their kidney disease, based on effective therapeutic options supported by accurate diagnosis and advanced prognostic tools.

Our expertise lies in identifying innovative products with the potential to address important medical needs and bringing them to the next stage of development to maximise their therapeutic and commercial value.


Averoa is developing a portfolio of innovative medicines to meet specific medical needs in nephrology. This portfolio currently consists of AVA1014, a product in the registration phase with the European Medicines Agency for the treatment of two complications associated with chronic kidney disease, and the LUCIOL project in the pre-clinical stage for the treatment of urinary lithiasis, which has orphan drug status in Europe and the United States.


Averoa aims to play a key role in the maturation of innovative projects in the field of kidney disease and defines itself as a “SMART DRUGS INCUBATOR”.




Why joined Lyonbiopole ?


As a health start-up, we feel the need to be part of an ecosystem in our region to exchange with our partners of tomorrow (subcontractors, medtech specialists, academic laboratories, etc.) but also to benefit from support for non-dilutive financing of our R&D projects.

Lyonbiopôle offers us access to numerous tools, advice and events essential to developing and structuring our business.



Sarah DELBAERE – CFO & Founder